Boston Scientific cuts full-year sales outlook: Can BSX sustain further downside pressure?

Traders Union
All News
Stocks
Boston Scientific drops 6.37% today

Highlights

Boston Scientific exceeded analyst expectations for third-quarter 2026 adjusted earnings per share and revenue but lowered its full-year sales outlook.
Management warned sales may decline in the fourth quarter due to continued cybersecurity disruptions and introduced a three-year restructuring plan targeting over $500 million in savings.
Shares of Boston Scientific currently trade below key moving averages, with technical signals indicating persistent downside risk and an expected range of $41.56 to $42.82 in the near term.

Profit outlook cut as cybersecurity incident outweighs earnings beat

Boston Scientific reported third-quarter 2026 results that marginally exceeded analyst expectations for both adjusted earnings per share and revenue, according to Seeking Alpha. However, the company cut its full-year 2026 sales outlook and warned of a decline in fourth quarter sales due to continued disruption from an August cybersecurity incident, leading to a negative shift in near-term revenue expectations. Management also initiated a restructuring program targeting over $500 million in savings over three years, according to Benzinga, as it anticipates ongoing challenges to sales and profitability growth through 2027.

Oversold momentum diverges from persistent sell signals at key resistance

BSX is trading below its MA-20 ($45.08) and MA-50 ($45.11), with further distance from the MA-200 at $57.3. Immediate resistance is identified at the Ichimoku Kijun level of $43.18. Momentum indicators show ongoing weakness, with both MACD and Awesome Oscillator favoring a sell bias and ADX registering neutral. RSI stands at an oversold 15.64, joined by Stochastic RSI, CCI, and Bull/Bear Power—all reflecting significant seller dominance intraday. There is a divergence, as oversold readings point to temporary exhaustion while momentum indicators continue to support a bearish undertone.

Sideways trade favored as breakout risks stay muted near term

Over the next two to three sessions, BSX is likely to remain within a typical volatility band ranging between $41.56 and $42.82. The probability of an upward breakout is low at 21%, and continued downside moves remain the prevailing scenario. Baseline expectations call for the price to remain in a sideways corridor, with any bullish shift depending on a sustained move above the $43.18 resistance, while further losses would be signaled by a break below the lower boundary of the anticipated range.

Viktoras Karapetjanc, expert at Traders Union, sees Boston Scientific’s near-term outlook as pressured by management’s sales cut and the ongoing fallout from the cybersecurity incident. He believes the company’s cautious guidance and restructuring efforts reflect a pragmatic approach to protect margins and restore momentum. Momentum signals and technical structure still favor the downside, but the oversold readings point to possible stabilization soon. "If BSX can hold above $41.56 and reclaim $43.18, I would view it as a constructive attempt to form a base for recovery."

Earlier, analysts noted that Boston Scientific faced sustained downside risks following operational and financial disruptions stemming from the August cyberattack. The latest quarter’s cautious outlook and restructuring efforts reinforce the bearish scenario, with market participants advised to watch for a decisive move below the $41.56 support for signs of further downside risk.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.